cystetic Medicines

cystetic Medicines is a clinical-stage biotechnology company dedicated to developing small-molecule anion channel correctors or "molecular correctors" to restore protein function in patients with cystic fibrosis (CF). Building on the research of Dr. Martin Burke from the University of Illinois at Urbana-Champaign and Dr. Michael Welsh from the University of Iowa, the company is currently focused on the development of CM001, a novel inhalable small-molecule therapy designed to restore ion balance and thereby reestablish lung host defense function for the treatment of cystic fibrosis. This approach utilizes state-of-the-art proprietary dry powder inhalation formulations to improve dose consistency and enable efficient delivery to the airways.